QIAGEN – Sample and Assay TechnologiesQIAGEN AGM, June 24, 2009, Venlo Slide: 2 Sample & Assay Technologies Safe Harbor Statement: Certain of the statements contained in this presentation

QIAGEN AGM, June 24, 2009, Venlo Slide: 1 Sample & Assay Technologies

QIAGEN – Sample and Assay Technologies

Annual General Meeting, Fiscal Year 2008Venlo, June 24, 2009

Peer M. SchatzChief Executive Officer


Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and geneticvaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations from certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. In addition certain statements contained in this news release are based on company assumptions, including, but not limited, to revenue allocations based on business segments. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).

Regulation G: The following slides contain certain summary information about QIAGEN N.V.’s sales, gross profit, operating income, net income, and earnings per share over a specific period and the comparable period, which information is presented on a “non-GAAP financial measures” basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press releases for information on the company’s operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.

Forward Looking Statements


Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, ...

Complexsample

DNAPureAnalyte

InformationAssayTechnologies

Target Detected

Yes

No

SampleTechnologies

Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins,

Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, ...

Sample & Assay Technologies


Revenues: 2008: $ 893 million 05–08 CAGR: 31%Net income1: 2008: $ 163 million 05–08 CAGR 33%EPS1: 2008: $ 0.80 05–08 CAGR: 20%

Product Range:>500 consumable products □ Sample technologies: to collect, separate, purify,

isolate, stabilize and store samples□ Assay technologies: to make such isolated target

information (DNA, RNA, proteins, etc.) visibleInstrumentation for above consumables

Customers (>400,000)Academic researchPharma/BiotechApplied Testing (veterinary, forensics etc.)Molecular Diagnostics

IP (03/09): >2’000 patents(750+ issued, 780+ pending, 500+ licensed)

Employees: >3‘000 employees based > 30 subsidiaries

1 excluding acquisition, integration and relocation related charges as well as amortization ofacquired IP and equity-based compensation (SFAS 123R)

QIAGEN at a Glance


Implementing our strategy

Where we have come from

How our strategy is performing

Achievements - Capabilities

Important milestones

Innovation

Examples

Outlook 2009

Corporate Goals

Investor Relations 2008

Corporate Governance

IR Activities

Share Price Development


SystemsBiology

Academia

MolecularDiagnostics

Applied Testing

PharmaceuticalIndustry

WorkflowStandardization

RNA

Protein

Market-segments

DNA

Sample & Assay Technologies

QIAGEN Strategy – Recap

Dis

sem

inat

ion

StandardizationQIAGEN2003


QIAGEN Organic GrowthSustainable and Industry Leading

Industry Leading Organic Growth

0%2%4%6%8%

10%12%14%16%18%20%

2005 2006 2007 2008

QIAGENIndustry average

(1) Industry data: Illumina, Luminex, Cepheid, Techne, GenProbe, Sigma Aldrich, Life Technologies (Invitrogen/Applied Biosystems),Bio Rad, Mettler, Meridian, Beckman, Waters, Becton Dickinson, Roche, Thermo, Millipore, Bruker, Celera, Affymetrix, QIAGEN

(1)


Human IDForensics

Applied Testing

Animal &Veterinary Testing

Pharmaceutical Industry

QIAGEN: Full Circle - One Core Focus

Academic Research

SampleTechnologies

AssayTechnologies

Molecular Diagnostics

Disseminating Technologies into Four Markets

BiosecurityBiodefense


Leading Position – Multiple Growth Drivers

Product and Technology Continuum

SAMPLETechnologies

ASSAYTechnologies

~$28% of sales

PublicPrivate

~20% of sales

DiscoveryDevelopment

~7% of sales

VeterinaryForensicsBio defense

~45% of sales

Sample TechAssay Tech: PCR etc.OEMRegulated assays

Life ScienceResearch

PharmaceuticalIndustry

AppliedTesting

MolecularDiagnostics


Human IDForensics

Applied Testing





Academic Research

SampleTechnologies

AssayTechnologies



1

Diagnostics


Molecular DiagnosticsStrong Current Market Position & Future

QIAGEN‘s PositionStrong brand, good reputation, large infrastructureCritical assays with a lot of penetration potentialFocused on broad portfolio and MDx laboratoriesAmong fastest growing companies in MDx >20%

Market SituationHigh market growth of 15-20%Decentralization of Molecular Diagnostics continuesMarket strongCapital constraints for smaller hospitals

OpportunitiesSelling breadthNeed for efficiency - Automation and process optimizationNovel markers - Innovation is key success factorPersonalized medicine

1

Diagnostics


Technology & Infrastructure

Largest sales & marketing forceLargest R&D budget in MDx technologiesLargest Intellectual property estateClose to complete technology portfolioLargest infectious disease assay portfolio

Market position

No. 1 in emerging countriesNo. 2 in PCR technology in MDxNo. 1 in HPV testingNo. 1 in automated sample processingNo. 1 in manual sample preparationNo. 1 OEM partner

(1) Excluding Viral Load and Blood Banking Business

Molecular Diagnostic Landscape (1) Leading Positions

Sales in US$ millions

Market Leadership in Molecular Diagnostics 1

Diagnostics

0

50

100

150

200

250

300

350

400

450

QIAGEN

Roche

MDx

GenProb

e

Abbott

Bayer

Cephe

id

~400

~350

~220

~150 ~140

~90


Increasing Importance of Medical Value Expected

IncreasingTesting efficiency

ImprovingMedical value

Value creation

2000 2010 2020

1

Diagnostics


Focus on Efficiency and Medical Value

Increasing Testing efficiency Improving Medical value

Value creation

2000 2010 2020

Integrated workflows

Infectious disease

Cervical Cx Screening Cancerstratification

Molecular Tumor Staging

HIV: Test &treatment

Ultra-fast , e.g. sepsis analysis

POC Antibiotics selection

Cancer screening

Integrated systems Point-of-care testing

Instrument size

Multiplexing

Menu breath

Data integration

Ease-of-use

High Resolution

Sensitivity Connectivity

Genetic screening

Infectious diseasegenotyping

Examples

1

Diagnostics


Sample Preparation Assay Setup Detection

Low Throughput

Modules(10-100/day)

Medium-HighThroughputModules

(50-250/day)

IntegratedSystem

(QIAsymphony)(50-250/day)

Consumables

Sample Technologies Assay Technologies

Complete Throughput Range

High ThroughputScreening

(QIAensemble)(250-6000/day)

1

Diagnostics


Sample Preparation Assay Set Up Detection

Low ThroughputModules

Endpoint (qualitative) PCR

QIAxcel

Medium-High ThroughputModules

Multiplexing

LiquiChip

Medium ThroughputFully integrated System

Real time (quantitative) PCR

RotorGene

High resolution sequence detection and quantification

PyroMark

Multiple Detection Capabilities

~400

1

Diagnostics


Assay Platform Potential Applications and Research

PyroMark KRAS, RUO, CE Pyrosequencing Colon cancer

PyroMark CpG p16, RUO Pyrosequencing Various cancers

PyroMark BRAF, RUO Pyrosequencing

Colon cancerMelanoma

Ovarian cancerThyroid cancer

PyroMark CpG MLH1, RUO PyrosequencingColon cancer

(hereditary forms)

PyroMark CpG MGMT, RUO Pyrosequencing Glioblastoma

PyroMark CpG LINE-1; RUO Pyrosequencing Various cancers

Fungi ITS2 Primers for PCR, ASR Pyrosequencing/Multiplex Antifungal treatment

MOTT 16S Primers for PCR, ASR Pyrosequencing/Multiplex Antibiotic resistance

artus TPMT LC PCR Kit, RUO, CE real-time PCRLeukemia,

Crohn’s Disease

artus MTHFR PCR Kit, RUO, CE real-time PCR Thrombosis, Atherosclerosis

Olerup SSP ® HLA-B*5701, RUO, CE real-time PCR AIDS

Companion DiagnosticsSelected Diagnostic Assays

CpG = positions of methylationRUO = (for) research use only

MDx instrumentPyroMark Q24

Complete platform

Complete toolbox

1

Diagnostics


HPV ScreeningSignificant Untapped Potential for HPV Testing

Adoption of existing guidelines

Communication: Patients, physicians

Key focus: market penetration, conversion to Pap+HPV

Creation of medical guidelines (>30 countries!)

Communication: Advocacy, patients, physicians,

Laboratory marketing (>20 players, QIAGEN ~70% share)

Creation of medical guidelines

Significant cost/benefit advantages

Emerging national (primary) screening programs

Substantial Market – Diverse Marketing Profiles

U.S.Current tests: ~ 11.4MPenetration: ~ 30%

EuropeCurrent tests: ~ 2.3MPenetration: ~ 7%

Asia/Latin America:Current tests: 0.9MPenetration: ~ 3%

Asia/LatinAmerica~ $280M

U.S.~ $490M

Europe~ $350M

Total: >$1.1 billionNote: Represents market from existing Pap Smear Tests onlySource: 4/24/07 Long Range Plan

1

Diagnostics


Molecular DiagnosticsStrategic Direction

BUILD

BUY:

EXTRACT:

Complete system projectsMenu on all platformsIncrease market penetration Brand equity

Relevant diagnostic content or IPAssets that strengthen QIAGEN’s market leadership in MDx

Revenue growthScale

1

Diagnostics


Human IDForensics

Applied Testing




Academic Research

SampleTechnologies

AssayTechnologies




2

Applied Test


Applied TestingMultiple Segments, Strong Potential

QIAGEN‘s PositionFocus segments: Genetic ID, Veterinary, BiosecurityGrowing assay portfolio, new: complete platformsStrong partnerships established

Market SituationMolecular methods further disseminated in applied fieldsMarket growth 15+%Overall testing markets today ~10% of MDx market volume

OpportunitiesLeverage strong installed base of instrumentationNew, expanded offerings from sample to resultGeographic expansion: Asia, Latin America, Middle EastBenefit from synergies with MDx

2

Applied Test


QIAGEN With Focus on Growth Markets

Development Introduction Growth Consolidation Saturation Decline

Applied Testing Market Segments Along Market Stage

GenID

Vet - production

Vet - companion

Food - GMO

Food - pathogen

Biosecurity

Food - ID

Quality control – pharma

Environmental

Quality control – personal care products

High

Fit to QIAGEN

Moderate

NAT Market2007 in Mio$

200

2

Applied Test


Applied TestingStrategic Direction

BUILD

BUY:

EXTRACT:

Build assay portfolioSales & Marketing channel globallyBrand equity New segment

Content, Assays and/or IP

Growth Synergy value

2

Applied Test


Human IDForensics

Applied Testing





Academic Research

SampleTechnologies

AssayTechnologies



3Pharma


Pharmaceutical IndustryDiscovery Fluctuating, Development Strong

QIAGEN‘s Position (approx 20% of sales)Unique offering „Research – Pharma – Diagnostic“Dedicated sales channelPersonalized medicine: Several collaborations in progress

Market SituationMolecular methods penetrating complete R&D value chainPersonalized medicine now realityDiscovery (10-12% of Q) constrainedDrug development (8-10% of Q): strongService organizations & academia supporting efforts

OpportunitiesPortfolio expansion into clinical areasNew platforms Strength in oncology assays

3Pharma


Pharmaceutical IndustryStrategic Direction

BUILD

BUY:

EXTRACT:

Awareness for today’s offeringContinuum “Research-Pharma-Diagnostics”Standardization

Assets which expand innovation leadership in Sample & Assay Technologies without diluting focus

Diagnostic contentSynergy in validation, regulatoryGrowth

3Pharma


Human IDForensics

Applied Testing





Academic Research

SampleTechnologies

AssayTechnologies



4Academia


Academic MarketsSource of Innovation

QIAGEN‘s PositionIn most segments QIAGEN with #1 or #2 positionAmong fastest growing companies in academic marketStrong brand and good reputation

Market SituationNew U.S. administration focus on innovation,Europe committed Scientific knowledge in Life Sciences increasingNew hot topics emerging faster and faster:

miRNAEpigenetics

OpportunitiesInnovation and quality leaderHigh growth areas: e.g. miRNA, EpigeneticsStimulus packages big upside

4Academia


19.375

17.773

16.648

15.455

14.257

12.247

10.219

8.796

7.349

5.772

4.044

2.3541.427919

0

5.000

10.000

15.000

20.000

25.000

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008

QIAGEN Quotes in Scientific Literature…

CAGR ~ 30%

4Academia

Number of Journal Articles citing QIAGEN Products and Protocols

Source: Medline, Pubmed, Scirus


Stimulus adding $14 billion in R&D funding until 2011$10 billion National Institutes of Health$3 billion National Science Foundation$1 billion NIST* and Department of DefenseStimulus impact potentially starting in Q4 2009Most of the funding in 2010

Our focus is on helping our customers access these fundsFormed a dedicated teamOutreach and support programs to customers with current and new grant proposals

Size of this opportunityImpact: difficult to quantify, min. $20 million in 2010Private and state funding situation

Potentially much more important:Long-term, “regular” increases in research funding planned (!)

http://www1.qiagen.com/productnews/StimulusSupport/default.aspx

U.S. Stimulus Program4Academia

NIST - National Institute of Standards and Technology


Academic ResearchStrategic Direction

BUILD

BUY:

EXTRACT:

Innovation leadershipStandardizationBrand equity differentiationAutomation in labs

Assets which expand innovation leadership in Sample & Assay Technologies without diluting focus

InnovationReputation

4Academia







Innovation

Examples

Outlook 2009

Corporate Goals



IR Activities



„Mexico Goes HPV“

Mexico Launches Campaign Against Cervical Cancer with HPV Screening


Sample Preparation Assay Setup Detection

Low Throughput

Modules(10-100/day)

Medium-HighThroughputModules

(50-250/day)

IntegratedSystem

(QIAsymphony)(50-250/day)

Consumables

Sample Technologies Assay Technologies

Complete Throughput Range

High ThroughputScreening

(QIAensemble)(250-6000/day)


Innovation – Measurement of Success

Awards

Products < 5 years old(1)

# of launched products ~ 250Revenues share ~28%


# of launched products ~ 250Revenues share ~28%

Products < 1 years old (1)

# of launched products 50Revenues share ~5%

Products < 1 years old (1)







QIAGENcares Program

QIAGENcares:Corporate Social Responsibility program in emerging countriesPublic-private partnerships:

Leading cliniciansCorporate partnersWomen’s advocacy groups

Focus on diagnostic tests:Fevers: Dengue, Malaria etc.Infectious disease: HPV, HIV, HBV, HCV, TB, others

Donation programs to initiate and facilitate implementation

QIAGENcares – initiatives:Donation program: 1 million HPV tests to GAVI countriesPartnered with:

CNCI* - HPV screening in IndiaCancer Foundation, China - nationwide HPV testingcareHPV development

Success Based on Social Responsibility*CNCI = Chittaranjan National Cancer Institute







Innovation

Examples

Outlook 2009

Corporate Goals



IR Activities



Where We Are – What Comes Next

Approaching US$1 billion in sales

Complete product and technology portfolio

Repositioning: from change management to growth management

Execution

Efficiency, effectiveness of actions

Strategy-centric to customer-centric

Execution

Solidify and expand bridgeheads/claims

Integrate/move complete portfolio

Platform advancement in time/spec

Content expansion

Expansion/defense of tech lead







Innovation

Examples

Outlook 2009

Corporate Goals



IR Activities



Highest Standards in Corporate Governance

QIAGEN N.V. is

1) Organized under the laws of Netherlands2) Listed on NASDAQ3) Listed in the Prime Standard Segment (TecDax) of the

Frankfurt Stock Exchange, Germany

QIAGEN placed highest standards on Corporate Governance Principles by endorsement of the codes of:

1) The Netherlands2) NASDAQ - Corporate Governance Rules3) Germany - Corporate Governance Code

Deviations from specific rules due to incompatibilities between these foreign regulations are explained in QIAGEN’s annual report which is published on QIAGEN‘s homepage (www.QIAGEN.com)

Highest Standards in Corporate Governance


QIAGEN Investor Relations 2008

1. Analyst Day in New York > 80 participants

Presentations on Conferences, worldwide 23

International Roadshows 25

Meetings with Investors, One-on-Ones > 600

Visits at QIAGEN in Germany and USA > 20


QIAGEN Investor Relations 2008

* Ratings not older than 90 days

Institutions (Banks, other) publishing research on QIAGEN: 30Analysts publishing research on QIAGEN: >35

Analysts’ Ratings* (per June 19, 2009)

0

2

4

6

8

10

12

14

16

Buy/Outperform Neutral Underperform


QIAGEN Shares vs. NASDAQ Biotech Index


QIAGEN Shares vs. TecDAX


Key Investment ConsiderationsStrong Growth at Low-Risk

Strong Strategic PositionAddressing high growth marketsFocused, complete and technology-leading portfolioCritical mass, well functioning organizationInnovation success – acquisition success

Innovation is keyProven innovation leadership in industry> 80 product launches in 20085% of revenue growth from new introduced products

Strong Financial Performance 2008 Revenue growth: 37%Organic adj. growth: 13%Operating cash flow up 98% to US$168 M in 2008


QIAGEN – Sample and Assay Technologies

Annual General MeetingFiscal Year 2008

Venlo, June 24, 2009


Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and geneticvaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations from certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. In addition certain statements contained in this news release are based on company assumptions, including, but not limited, to revenue allocations based on business segments. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).

Regulation G: The following slides contain certain summary information about QIAGEN N.V.’s sales, gross profit, operating income, net income, and earnings per share over a specific period and the comparable period, which information is presented on a “non-GAAP financial measures” basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press releases for information on the company’s operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.

Forward Looking Statements


Agenda

1. Opening


2. Managing Board Report for the Year endedDecember 31, 2008, (“Fiscal Year 2008”)

Agenda


Exceeded revenues guidance US$893.0 MStrong organic revenue growth

Overall 13%MDx growth, HPV a strong driver >20%

EPS, adj. reached high end US$ 0.80Operating income, adj. growth 54%Record revenues from 12 mo new products 5%Underlying fundamental momentum

Acquired CorbettAdded Rotor-Gene Real Time PCR CyclersAdded CAS Assay Setup System

Acquired pyrosequencing technology and product portfolio

>80 new products in 2008: focus on automation,genotyping, and functional analysis5 new MDx assays launched

2009 launches include: QIAsymphony AS , QIAgility, PyroMark, EZ1 Advanced XL, RotorGene Q, QIAxtractor

Strategic and Other

Financials

Fiscal Year 2008Overview

Adjusted figures exclude business integration and relocation related charges as well as amortization of acquired intangibles and equity-based compensation (SFAS 123R). EPS 2008 includes a non-cash tax charge of US$ 0.01 from revaluation of acquired tax positions.


200

300

400

500

600

700

800

900

1000

2005 2006 2007 2008

20

30

40

50

60

70

80

90

2005 2006 2007 2008

CAGR2005-2008 = 31%

CAGR2005-2008 = 20%R

even

ues

in U

S$m

EPS,

adj

. in

US$

cen

t

Revenue and EPS, adj. Growth 2005 - 2008

+US$243 M

+US$0.17

Adjusted figures exclude business integration and relocation related charges as well as amortization of acquired intangibles and equity-based compensation (SFAS 123R). EPS 2008 includes a non-cash tax charge of US$ 0.01 from revaluation of acquired tax positions.


Fiscal Year 2008 Revenue Distribution

RoW

Americas49% growth50% growth CER

Europe21% growth17% growth CER

By Product Groups By Geographic Regions

88%

11%

50% 37%

10%

Others

CER = Constant Exchange Rates

Sample and Assay Technologies36% growth34% growth CER

Instruments51% growth52% growth CER

Asia24% growth16% growth CER


Significant Sales and Marketing PowerAs of December 31, 2008

> 1,300 Sales and Marketing Professionals

Americas Approx 50% of Sales: Sales and Marketing Force: 511

Europe Approx 37% of SalesSales and Marketing Force: 513

Asia Approx 10% of SalesSales and Marketing Force: 272

MARKETS

Biomedical

MDx

Inside SalesE-commerce

Appl. Testing

SPECIALISTS

Channels

Pharma

Research


300

400

500

600

700

800

900

1000

RevenuesFY 2007

Price Volume Newproducts

Acquisitions Exchangerates

RevenuesFY 2008

0

Organic Growth 13%

~ 2%

~ 5%~ 6%

~ 37%~ 22%

US$M

Fiscal Year 2008Growth Drivers

New Products and Volume Drive Strong Organic Growth

~ 2%


2008 2007 Growth

Net sales (US$M) 893.0 649.8 37%

Operating income (US$M), adj.1 252.7 164.3 54%

Operating margin, adj.,1 28% 25%

Net income (US$M), adj.1,2 163.3 111.5 47%

EPS (US$), adj.1,2 0.80 0.63 27%

Big Jump in Operating Margin, adj. to 28%

Fiscal Year 2008At a Glance

1 Excluding business integration and relocation related charges as well as amortization of acquired IP andequity-based compensation (SFAS 123R)

2 Including a non-cash tax benefit of US$ 0.02 per share in 2007 and including a non-cash tax charge of US$ 0.01 per share from revaluation of acquired tax positions in 2008


Strong Balance Sheet Structure

50%50%Equity ratio

In US$ millionsexcept share data Fiscal 2008 Fiscal 2007 Change

Cash & cash equivalents 333.3 347.3 -4%

Working capital 441.2 482.2 -9%

Total assets 2,885.3 2,775.2 4%

Total long term liabilities 1,169.1 1,217.3 -4%

Total shareholders’ equity 1,453.8 1,391.6 4%

Number of shares outstanding 197,839,113 195,335,076 1%

Fiscal Year 2008Balance Sheet


Current Debt Maturity Profile

Notes: (a) Revolving Credit Facility - currently not drawn(b) conversion price US$12.64(c) final maturity in 2024 – first investor put/issuer call in 2011(d) conversion price US$20.00(e) final maturity in 2026 – first investor put/issuer call in 2013

Maturities of QIAGEN’s current main debt instruments

amount in US$m 2009 2010 2011 2012 2013

Syndicated RCF 150 150

Term Loan 500 25 50 75 350

Convertible Bond 2004 145 150

Convertible Bond 2006 300 300

25 50 75 350

(a)

(b) (c)

(d) (e)


Development of Net Debt and EBITDA

Historic development of net debt and EBITDA (a)

Leverage rationet debt / EBITDA (a)

Notes: (a) Adjusted figures excluding acquisition, integration and restructuring related charges as well as equity-basedcompensation (SFAS 123R)

636 645

3 26

127143

195

290

113

0

100

200

300

400

500

600

700

800

900

1,000

2004 2005 2006 2007 2008

in U

S$m

0

50

100

150

200

250

300

350

in US

$m

Net Debt (lhs) EBITDA (rhs)

-0.10.0

3.3

0.2

2.2

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

2004 2005 2006 2007 2008

Net Debt / EBITDA


20%1,585,5581,908,161Balance at December 31

-9,469-93,621RSUs forfeited

205%-127,273-388,342RSUs vested

-7%864,855804,566RSUs granted

857,445-RSUs assumed in acquisition

-1,585,558Balance at January 1

ChangeFiscal 2007Fiscal 2008Restricted Stock Units (RSUs)

Stock Options Fiscal 2008 Fiscal 2007 ChangeBalance at January 1 11,362,641 11,716,539

Options assumed in acquisition - 4,139,854

Options granted 432,725 379,598 14%

Options exercised -1,340,914 -4,551,655 -71%

Options forfeited -179,456 -321,695

Balance at December 31 10,274,996 11,362,641 -10%

Stock Options and Restricted Stock Units (RSUs)Summary of Changes


In US$ millions unless indicated 2008 2007Net income 89.0 50.1

Depreciation & amortization 105.7 62.6

Purchased in-process R&D 1.0 25.9

Others, net (22.7) (53.8)

Operating cash flow 173.0 84.8

Capital expenditures (39.4) (34.5)

Free cash flow1 133.6 50.3

1 Free cash flow computed using net cash from operating activities less capital expenditures

Fiscal Year 2008Cash Flow and Balance Sheet Key Figures

In US$ millions unless indicated As of 12/31/2008Cash and cash equivalents 333Net debt 645Near term payment obligations(next 12 months) 25Equity ratio 50%Net debt / EBITDA, adj. ratio 2.2


2005 2006 2007 2008

2005 2006 2007 2008

Inventory Days

Receivables-DSO

Target 2008140 days

Managing Working CapitalAnnual Average Key Figures

All figures to be read asannual average.

Target 200860 days

Industry standard70 days

165

154

143

58 61 60

147

61


Americas Europe Asia RoWTotal2008

Total2007 Growth

Production 260 382 57 56 755 650 16%

R&D 111 378 20 20 529 461 15%

Sales 437 392 253 33 1,115 925 21%

Marketing 74 121 19 4 218 229 -5%

Admin 138 209 60 17 424 397 7%

Total 1,020 1,482 409 130 3,041 2,662 14%

Employees December 31, 2008

Development Programs Available for most of our 3,000 Employees make QIAGEN“Top Employer” in Germany in 2008 by Handelsblatt

Ranked No.1 in the field of Personnel Development in 2009


3. Supervisory Board Report on the Company'sAnnual Accounts (the "Annual Accounts")for Fiscal Year 2008

Agenda


4. Adoption of the Annual Accountsfor Fiscal Year 2008

Agenda


5. Reservation and dividend policy

Agenda


6. Approval of the performance of theManaging Board during Fiscal Year 2008, including a discharge from liability with respect to the exercise of their dutiesduring Fiscal Year 2008

Agenda


7. Approval of the performance of theSupervisory Board duringFiscal Year 2008, including a dischargefrom liability with respect to the exerciseof their duties during Fiscal Year 2008

Agenda


8. Reappointment of

Dr. Werner Brandt, Dr. Metin Colpan,Mr. Erik Hornnaess, Prof. Dr. Manfred Karobath,Mr. Heino von Prondzynski, and Prof Dr. Detlev H. Riesner

as Supervisory Directors of the Companyfor a term ending on the date of theAnnual General Meeting in 2010

Agenda


9. Reappointment of

Mr. Peer M. Schatz,Mr. Roland Sackers,Dr. Joachim Schorr, andMr. Bernd Uder

as Managing Directors of the Companyfor a term ending on the date ofthe Annual General Meeting in 2010

Agenda


10. Reappointment of Ernst & YoungAccountants as auditors of theCompany for the fiscal year endingDecember 31, 2009

Agenda


11. Authorization of the Managing Board,until December 24, 2010,to acquire shares in theCompany’s own share capital

Agenda


12. Questions

Agenda


4. Adoption of the Annual Accounts for Fiscal Year 2008

has been adopted

6. Approval of the performance of the Managing Board duringFiscal Year 2008, including a discharge from liability withrespect to the exercise of their duties during Fiscal Year 2008

has been adopted

Summary


7. Approval of the performance of the Supervisory Board during Fiscal Year 2008 including a discharge from liability with respect to the exercise of their duties duringFiscal Year 2008

has been adopted

8. Reappointment of Dr. Werner Brandt , Dr. Metin Colpan,Mr. Erik Hornnaess, Prof. Dr. Manfred Karobath, Mr. Heino von Prondzynski, and Prof Dr. Detlev H. Riesneras Supervisory Directors of the Company for a termending on the date of the Annual General Meeting in 2010

has been adopted

Summary


9. Reappointment of Mr. Peer M. Schatz,Mr. Roland Sackers, Dr. Joachim Schorr, andMr. Bernd Uder as Managing Directors of the Companyfor a term ending on the date of theAnnual General Meeting in 2010

has been adopted

10. Reappointment of Ernst & Young Accountants asauditors of the Company for the fiscal year endingDecember 31, 2009

has been adopted

11. Authorization of Managing Board, until December 24, 2010, to acquire shares in the Company's own share capital

has been adopted

Summary


13. Closing of

QIAGENAnnual General MeetingFiscal Year 2008

June 24, 2009

Agenda


Thank you very much for joining

QIAGEN‘sFiscal 2008 Annual General Meeting

Have a good journey home!

Documents

QIAGEN – Sample and Assay TechnologiesQIAGEN AGM, June 24, 2009, Venlo Slide: 2 Sample & Assay Technologies Safe Harbor Statement: Certain of the statements contained in this presentation